ALFA Finder
08:26 IST
NSE
Business Update
Biocon Business Update
Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.
Biocon Ltd
Biocon Ltd news stories on ALFA NewsRead the news →- Share price
- ₹368.05
- Market cap
- ₹59,981 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 132.7×Sector 43.8×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Earnings Call 6Other Announcement 5Annual General Meeting 5Capital Structure Change 4Business Update 4Regulatory Approval 3New Order Win 3Management Change 3Results Update 2Financial Results 2Board Meeting Date 2Product Launch 1Partnership 1Merger & Restructuring 1Legal & Regulatory 1Employee Stock Options 1Annual Report 1Acquisition 1
Time
4 announcements with these filters
08:26 IST
NSE
Business Update
Biocon Business Update
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
08:40 IST
NSE
Business Update
Biocon Business Update
Biocon's US subsidiary received U.S. FDA approval for the Yesintek® prefilled autoinjector. This supplemental approval enhances the company's immunology portfolio.
08:41 IST
BSE
Business Update
Biocon Business Update
Biocon announced the publication of Phase III clinical data supporting the effectiveness of its biosimilar Yesafili™. The data reinforces clinical equivalence ahead of its US launch.